West Nile Virus Human IgM Assay Control BC141M

$94.00

Summary

Virion/Serion Diagnostic Kit Control for research use (RUO)
West Nile Virus Human IgM Assay Control, recombinant
Applications: ELISA
Suitable for IgM detection
Ready-to-use; pre-diluted for SERION ELISA classic and SERION ELISA antigen assays
3 mL

SKU: BC141M Category: Virion/Serion kits Tags: ELISA control serum, IgM, West Nile Virus

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	West Nile Virus reactive IgM
species reactivity	West Nile Virus
applications	ELISA
assay type	Indirect & quantitative
available size	1 mg

West Nile Virus Human IgM Assay Control BC141M

kit
Research area Infectious Disease
Storage Store at 2-8°C.
Form liquid
Associated products West Nile Virus Human IgG Assay Control (BC141G) West Nile Virus Human IgM Assay Control (BC141M) West Nile Virus IgG ELISA Kit (ESR141G) West Nile Virus IgM ELISA Kit (ESR141M)

target relevance

human antibody anti-West Nile Virus

West Nile Virus

Description
Virus that causes West Nile fever and neuroinvasive disease

Structure
West Nile virus (WNV) is an enveloped, positive-sense, single-stranded RNA virus belonging to the genus Flavivirus within the family Flaviviridae. The virus is closely related to other medically important flaviviruses, including Japanese encephalitis virus, St. Louis encephalitis virus, Dengue virus, and Zika virus. West Nile virus is maintained in nature through transmission cycles involving mosquitoes, primarily Culex species, and avian reservoir hosts. Humans and horses are considered incidental or dead-end hosts because they typically do not develop sufficient viremia to sustain transmission. Following mosquito-borne inoculation, the virus can disseminate to multiple tissues and, in some cases, invade the central nervous system. Since its introduction into North America in 1999, West Nile virus has become one of the most important mosquito-borne viral pathogens in the Western Hemisphere.

Diagnosis
The diagnosis of West Nile virus infection is performed through serological and molecular methods. Detection of West Nile virus-specific IgM antibodies in serum or cerebrospinal fluid using ELISA is the most commonly employed diagnostic approach and is particularly useful in patients with neurological disease. Confirmation may be obtained through plaque reduction neutralization testing (PRNT) to distinguish West Nile virus infection from other flaviviral infections. Reverse transcription polymerase chain reaction (RT-PCR) can detect viral RNA during the early phase of infection but is generally less sensitive because viremia is often transient and low-level. Cerebrospinal fluid analysis in neuroinvasive disease typically demonstrates lymphocytic pleocytosis and elevated protein concentrations. Laboratory confirmation is important because clinical symptoms overlap with numerous other viral infections and causes of encephalitis.

Symptoms
Approximately 80% of West Nile virus infections are asymptomatic. Symptomatic individuals typically develop illness following an incubation period of approximately two to fourteen days. West Nile fever commonly presents with fever, headache, fatigue, malaise, muscle aches, joint pain, nausea, vomiting, and occasionally a maculopapular rash. Most patients recover completely within days to weeks. A small proportion of infected individuals, particularly elderly or immunocompromised patients, develop neuroinvasive disease characterized by meningitis, encephalitis, or acute flaccid paralysis. Neurological manifestations may include severe headache, neck stiffness, confusion, altered mental status, tremors, seizures, muscle weakness, and paralysis. Severe neuroinvasive disease can result in long-term neurological deficits, respiratory failure, or death.

Data

FAQ & Publications

Frequently Asked Questions

What is the intended application of the West Nile Virus Human IgM Assay Control BC141M?

The West Nile Virus Human IgM Assay Control BC141M is designed for use in ELISA applications to detect human IgM antibodies specific to West Nile Virus. It is suitable for indirect and quantitative assay types and is pre-diluted for compatibility with SERION ELISA classic and SERION ELISA antigen assays.

How should the West Nile Virus Human IgM Assay Control BC141M be stored to maintain its stability?

This assay control should be stored at 2-8°C to ensure its stability and preserve its reactivity for research use.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.

Protocols

relevant to this product
BC141M protocol

Documents

#
Please enter your product and batch number here.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

West Nile Virus Human IgM Assay Control BC141M

Data

FAQ & Publications

Protocols

Documents

Related Technical Resources & Posts

Reviews

Related Products

Enterovirus IgM Control Serum BC133M

Candida albicans IgM Control Serum BC117M

Influenza B Virus IgM Control Serum BC1232M

Campylobacter jejuni IgM Control Serum BC139M

Influenza A Virus IgM Control Serum BC1231M

Brucella IgM Control Serum BC116M

Helicobacter pylori IgM Control Serum BC118M

Borrelia burgdorferi IgM Control Serum BC121M

Aspergillus fumigatus IgM Control Serum BC132M

Echovirus IgM Control Serum BC135M

Cytomegalovirus IgM Control Serum BC109M

Coxsackie IgM Virus Control Serum BC134M

Coxiella burnetii Phase 2 IgM Control Serum BC1312M

Chlamydia trachomatis IgM Control Serum BC1372M

Chlamydia pneumoniae IgM Control Serum BC1371M